Postexposure prophylaxis with nirmatrelvir-ritonavir does not cut COVID-19 Infection
Jul 18, 2024
No significant reduction was seen in the risk for symptomatic SARS-CoV-2 infection with postexposure prophylaxis for five or 10 days.
Hospital-onset SARS-CoV-2 infection during omicron linked to morbidity
Jul 15, 2024
Hospital-onset SARS-CoV-2 remained associated with increased morbidity and mortality during the omicron era.
Long COVID incidence declined over course of pandemic
Jul 23, 2024
The authors say, however, that the risk remained substantial, even among vaccinated persons during the omicron era.
Dementia rate decline accelerates during COVID-19 pandemic
By
Eliza Mattson
Jul 23, 2024
Before the COVID-19 pandemic, the rate of older adults living with dementia was decreasing. The pandemic accelerated that decline, however, due to an increase in deaths among older adults living with dementia,...
Nearly one in four do not recover from COVID-19 by 90 days
Jun 19, 2024
Female sex and preexisting cardiovascular disease were tied to longer recovery times.
CDC advises updated COVID vaccine for everyone over 6 months of age
Jun 28, 2024
Americans 65 and older account for two-thirds of COVID hospitalizations and 82% of in-hospital deaths, yet only about 40% of Americans in that age group were immunized with the COVID vaccines that were...
Residual risk seen for death, postacute sequelae in third year after COVID-19 hospitalization
Jun 13, 2024
The risk for death remains significantly elevated in the third year, as is risk for incident postacute sequelae of COVID-19.
Systemic side effects of COVID-19 vaccine tied to greater nAB response
Jun 11, 2024
Each 1-degree Celsius increase in skin temperature after a dose was linked to a 1.8- and 3.1-fold higher neutralizing antibody response one and six months later.
Nirmatrelvir-ritonavir no aid for long COVID symptoms
Jun 10, 2024
The findings based on symptoms at 10 weeks following 15-day course in vaccinated cohort.
No decline in cardiovascular events seen with COVID-19 vaccine after acute coronary syndromes
Jun 03, 2024
Findings show no significant reduction in primary end point, MACE for those receiving vaccine after acute coronary syndromes